Aandeel A140410 MEZZION PHARMA CO.,LTD.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Mezzion Pharma Co.,Ltd.

Aandelen

A140410

KR7140410002

slotkoers Korea S.E.
Andere beurzen
 00:00:00 30-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
37.750 KRW -2,45% Intraday-grafiek van Mezzion Pharma Co.,Ltd. +2,58% -3,21%
18/03 Mezzion Pharma Co. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023 CI
2023 Mezzion Pharma Co. rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2023 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Mezzion Pharma Co.,Ltd. announced that it has received KRW 49.99999719 billion in funding from BRV Capital Management and other investors
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Mezzion Pharma to Raise 50 Billion Won From Share Sale
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 49.99999719 billion in funding from BRV Capital Management
Mezzion Pharma Co.,Ltd. Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Mezzion Pharma Co.,Ltd. Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Mezzion Pharma Announces Positive Data Presented to FDA in Type C Meeting
Mezzion Pharma Co.,Ltd. announced that it has received KRW 20 billion in funding
Mezzion Pharma Co.,Ltd. announced that it expects to receive KRW 20 billion in funding
Mezzion Appoints William Breitenbach as Chief Commercial Officer for Mezzion's Global Commercial Operations
Mezzion's New Drug Application for Its Orphan Drug Udenafil for the Treatment of Single Ventricle Heart Disease Has Been Accepted for Filing by the FDA
Mezzion Pharma Co. Ltd. Announces Re-Submission of New Drug Application for its Orphan Drug Udenafil
Mezzion Pharma Co. Ltd. Announces Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients
Mezzion Pharma's Announces Results from the Pivotal 400-Subject Phase 3 Fuel Trial
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers A140410
  4. Nieuws Mezzion Pharma Co.,Ltd.
  5. Andere talen